Bright51: Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients (clinicaltrials.gov) - May 23, 2026 - P3 | N=29 | Completed | Sponsor: Chiesi Farmaceutici S.p.A. | Active, not recruiting ➔ Completed
Trial completion • Fabry Disease • Genetic Disorders
|